A PYMNTS Company

US: Mallinckrodt must face investors’ antitrust suit

 |  August 1, 2019

Mallinckrodt must face a proposed class action lawsuit alleging it failed to disclose an imminent US$100 million Federal Trade Commission settlement resolving claims it illegally maintained a monopoly over an expensive drug, a federal judge has ruled.

US District Judge Dabney Friedrich in Washington, DC, on Tuesday, July 30, also held the plaintiffs sufficiently alleged the drugmaker and top executives misled investors about H.P. Acthar Gel’s reimbursement by Medicare and Medicaid and 2017 sales prospects.

Full Content: Reuters

Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.